Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBIT Margin: 2012-2025

Historic EBIT Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to -907.37%.

  • Agios Pharmaceuticals' EBIT Margin rose 23956.00% to -907.37% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,061.80%, marking a year-over-year increase of 17630.00%. This contributed to the annual value of -1,166.47% for FY2024, which is 29305.00% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its EBIT Margin stood at -907.37% for Q3 2025, which was up 11.05% from -1,020.12% recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' EBIT Margin peaked at -907.37% during Q3 2025, and registered a low of -12,156.85% during Q1 2022.
  • In the last 3 years, Agios Pharmaceuticals' EBIT Margin had a median value of -1,221.97% in 2025 and averaged -1,244.15%.
  • Its EBIT Margin has fluctuated over the past 5 years, first spiked by 1,054,136bps in 2023, then tumbled by 9,763bps in 2025.
  • Agios Pharmaceuticals' EBIT Margin (Quarterly) stood at -2,300.97% in 2022, then soared by 80,475bps to -1,496.23% in 2023, then soared by 33,092bps to -1,165.30% in 2024, then soared by 23,956bps to -907.37% in 2025.
  • Its EBIT Margin stands at -907.37% for Q3 2025, versus -1,020.12% for Q2 2025 and -1,221.97% for Q1 2025.